Publications

Long-acting injectables for global health: drug development considerations and applications in malaria and tuberculosis.

Date Published: October 14, 2026
Long-acting injectable (LAI) drug formulations represent a transformative modality in modern therapeutics, delivering medications that maintain therapeutic effects over extended periods. While initially developed to improve patient adherence and acceptability for applications such as hormonal contraception and chronic conditions, including psychiatric disorders, their recent success in HIV treatment and prevention…

Development of GuaB Inhibitors to Treat Mycobacterium tuberculosis Infection.

Date Published: October 9, 2026
Mycobacterium tuberculosis (Mtb) is responsible for more deaths per year than any other infectious disease. Resistance of circulating Mtb to the standard of care treatment regimen is an urgent global health crisis for which novel antibiotic treatments are needed. We have developed extremely potent, orally bioavailable, small-molecule inhibitors of inosine…

Dosing and Safety of Once-Weekly Rifapentine and Isoniazid for 12 Weeks for Tuberculosis Preventive Therapy in Children With and Without HIV: Protocol for a Phase I/II Open-Label, Exposure-Controlled, Dose-Finding, and Safety Study (Tuberculosis Trials Consortium Study 35).

Date Published: September 30, 2026
Young children with exposure to or infection with are at high risk of developing tuberculosis disease, and postexposure tuberculosis preventive treatment decreases this risk. Evidence is limited regarding the dosing and safety of the 12-dose once-weekly rifapentine and isoniazid regimen (3HP) for tuberculosis preventive treatment in children younger than 2…

Structural and Mechanistic Studies of ADEPs Yield Potent Antibacterials and a Drug Formulation Strategy for Tuberculosis.

Date Published: September 24, 2026
Acyldepsipeptides (ADEPs) are potent ClpP dysregulators that are active against a range of Gram-positive bacteria, but have limited potency against Mycobacterium tuberculosis (Mtb). To address potency, we employed a strategy of macrocycle rigidification and side-chain optimization enabled by a novel solid-phase peptide synthesis route. Among 35 compounds synthesized, ADEP 19…

Ubiquitylation by the GID/CTLH complex regulates the metabolic and innate immune response of macrophages to infection by Mycobacterium tuberculosis.

Date Published: September 18, 2026
The GID/CTLH E3 ligase complex is implicated in several biological processes, yet its full substrate repertoire remains poorly defined. We recently identified the complex as a broad modulator of macrophage responses to Mycobacterium tuberculosis (Mtb) infection. Here, we use label-free proteomics and diGly capture analysis of Mtb-infected macrophages to define…

Adaptive immunity shapes baseline physiology of in high-dose versus low-dose infection BALB/c mouse drug treatment models.

Date Published: September 2, 2026
Preclinical tuberculosis (TB) drug evaluation relies heavily on mouse infection models. Drug efficacy varies depending on inoculum and the timing of treatment initiation. These differences reflect, in part, physiological adaptations of () to host immune pressure. We used novel molecular markers of pathogen health (RS ratio and SEARCH-TB) to contrast…

Central nervous system antituberculosis drug exposures in a rabbit model of tuberculous meningitis.

Date Published: August 5, 2026
Treatment optimization through pharmacokinetic evaluation is needed to improve outcomes in tuberculous meningitis (TBM). Clinical assessment of drug penetration into the central nervous system (CNS) is limited to cerebrospinal fluid (CSF) sampling, which may not reflect drug exposures at the site-of-disease. We characterized the pharmacokinetics of antituberculosis drugs in CNS…
Courtesy of the U.S. National Library of Medicine